Ask AI
ProCE Banner Activity

Evolving Standard of Care for Frontline TKI Therapy in CP-CML Clinical Practice

Slideset

Download these slides from an ASH 2025 live satellite symposium on considerations for selecting frontline therapy for patients with CP-CML, including evaluation of the latest clinical data and prognostic scoring systems, and expert-recommended best practices.

Released: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals who care for patients with chronic-phase chronic myeloid leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement individualized strategies for frontline treatment of chronic-phase CML based on clinical trial evidence, patient-specific factors, and BCR::ABL1 mutation status

  • Conduct optimal molecular and mutational monitoring during TKI treatment to guide the timing of therapy changes and subsequent therapy decisions in patients with chronic-phase CML

  • Select optimal subsequent therapy for patients with CP-CML who progress on or become intolerant to frontline TKI treatment

  • Differentiate important defining characteristics between TKIs and how these attributes influence efficacy and safety outcomes in chronic-phase CML